Haemophilia A News and Research

RSS

Hemophilia A is an X-linked, recessive, bleeding disorder caused by a deficiency in the activity of coagulation factor VIII. Affected individuals develop a variable phenotype of hemorrhage into joints and muscles, easy bruising, and prolonged bleeding from wounds. The disorder is caused by heterogeneous mutations in the factor VIII gene which maps to Xq28.

New York Governor participates in roundtable discussion on stem cell research

Albert Einstein College of Medicine of Yeshiva University hosted a roundtable discussion on stem cell research with New York Governor David A. Paterson today. Allen M. Spiegel, M.D., the Marilyn and Stanley M. Katz Dean of Einstein, and eight stem cell researchers discussed advances in medical therapies and treatments that Einstein scientists have been investigating since receiving more than $14 million in State funding for stem cell research.

9 Oct 2009

Amorfix Life Sciences to present Amorfix's EP-vCJD blood screening test for vCJD at WFH Global Forum

Amorfix Life Sciences, a company focused on treatments and diagnostics for brain wasting diseases, announced today that its Chief Executive Officer, Dr. George Adams, will present Amorfix's EP-vCJD(TM) blood screening test for variant Creutzfeldt-Jakob Disease ("vCJD") at the Sixth World Federation of Hemophilia ("WFH") Global Forum on the Safety and Supply of Treatment Products for Bleeding Disorders in Montreal, Quebec at 11:00 am ET on Friday, September 25, 2009.

24 Sep 2009

CSL Behring offers new dosage strength of Helixate FS in U.S.

Hemophilia A patients who require high doses of Helixate® FS, Antihemophilic Factor (Recombinant), can now benefit from greater convenience in administering their treatment, thanks to a new 3000 IU (international unit) dosage strength. CSL Behring announced today that this new dosage strength is available in the U.S., allowing many patients to reduce reconstitution time by eliminating the need to mix and pool multiple vials of Helixate FS.

22 Sep 2009

Inhibitor Education Summits to address pertinent topics regarding hemophilia

More than 160 families of patients living with a rare form of hemophilia are coming together at educational summits sponsored this fall by the National Hemophilia Foundation (NHF) and the Center for Biomedical Continuing Education (CBCE). For the fifth year, the Inhibitor Education Summits will connect patients and their families with expert healthcare professionals and fellow patients to address pertinent topics such as effective pain management, exercise and nutrition, financial security, and psychological wellbeing.

29 Aug 2009

Medgenics' EPODURE tissue Biopumps platform technology effective in maintaining hemoglobin levels

Medgenics is pleased to announce that one of the patients, who was treated with the Company’s EPODURE tissue Biopumps almost 11 months ago, continues to be effectively treated for anemia without a single erythropoietin (EPO) injection. This patient (#2) was dependent on frequent injections of the therapeutic protein (EPO) for the 18 months prior to receiving a single administration of 3 tiny EPODURE tissue Biopumps in the Company’s phase I/II anemia trial in Israel.

27 Aug 2009

Prevention and eradication of FVIII antibodies could improve hemophilia treatment

Octapharma AG is leading an international initiative focused on confronting the major risk associated with hemophilia A therapy - anti-factor VIII (FVIII) antibodies, also known as inhibitors. This initiative, combined with Octapharma's efforts to pursue the first recombinant FVIII therapy produced from a human cell line, could dramatically impact the treatment of an estimated one in every 5,000 to 10,000 men born with hemophilia A worldwide.

27 Aug 2009

FDA approves Helixate FS for routine prophylaxis in children with hemophilia A

CSL Behring announced today that Helixate® FS, Antihemophilic Factor (Recombinant), has been approved by the U.S. Food and Drug Administration (FDA) for routine prophylaxis in children with hemophilia A who are 16 years old or younger and do not have pre-existing joint damage.

17 Aug 2009

Amsterdam Molecular Therapeutics reports 2009 half year financials

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today reported its results for the first half year of 2009.

13 Aug 2009

NIH stimulus funding supports Emory - grants to advance research, create jobs, support students

At least 50 research projects so far, supported by more than $10 million in stimulus grants from the National Institutes of Health, are expected to lead to new discoveries at Emory University that will improve medical treatment, create new jobs, and provide additional educational opportunities for students. Emory has received half of all the NIH ARRA grants awarded to Georgia academic institutions thus far.

9 Aug 2009

Research supports world blood donor day message on blood safety

Other countries could learn from the mistakes made in UK blood policy concludes research awarded by the Economic and Social Research Council's Michael Young Prize.

13 Jun 2009

Medgenics’ phase I/II clinical trial shows EPODURE continuous anemia treatment lasting 5 months in kidney disease patients

Medgenics has announced that the latest, encouraging results of the Company's ongoing EPODURE Biopump Phase I/II Clinical Trial were presented at the 45th Conference of the Israeli Society of Nephrology and Hypertension, in Israel on March 27, 2009.

29 Mar 2009

New tissue engineering technique may help stem cells generate solid organs

Stem cells can thrive in segments of well-vascularized tissue temporarily removed from laboratory animals, say researchers at the Stanford University School of Medicine.

2 Mar 2009

Gene therapy for rheumatoid arthritis: promising results

Researchers have reported the first clinical evidence that gene therapy reduces symptoms in patients with rheumatoid arthritis, an important milestone for this promising treatment which has endured a sometimes turbulent past.

27 Jan 2009

CSL Behring receives FDA approval of RiaSTAP

CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for RiaSTAP(TM), the first and only treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.

19 Jan 2009

A new method to control bleeding in hemophilia

Investigators at Children's Research Institute, BloodCenter of Wisconsin's Blood Research Institute and the Medical College of Wisconsin have discovered a new way to help the blood clot by having the missing clotting factor packaged in the patient's own platelets.

13 Nov 2008

FDA licenses Kogenate FS to prevent joint damage in children with hemophilia A

The U.S. Food and Drug Administration has approved a new use for the blood product Kogenate FS to reduce the frequency of bleeding episodes and prevent joint damage in children with the most severe form of hemophilia.

12 Oct 2008

Some Northern California colleges banning campus blood drives because of FDA's policy barring MSM

Some colleges in Northern California have banned campus blood drives, saying that FDA's lifetime ban on donations from men who have had sex with men violates the schools' nondiscrimination policies, NPR's "All Things Considered" reports.

17 Jun 2008

Maxygen receives approval for trial of factor VIIa in UK

Maxygen, Inc. today announced that it has filed a Clinical Trial Authorization (CTA) and received the necessary approvals in the United Kingdom to initiate a first-in-human Phase I trial of MAXY-VII in hemophilia patients.

11 Jun 2008

CSL Behring study shows extended half-life recombinant VIIa leads to longer biologic activity

CSL Behring today presented results of a pre-clinical study that not only demonstrates the feasibility of genetically fusing factor VIIa to human albumin, but that this therapeutic protein with a prolonged half-life can lead to a longer biologic effect.

3 Jun 2008

Chemically modified protein may help people with hard-to-treat hemophilia

Pathologists at The University of Texas Health Science Center at Houston have developed a chemically modified protein that may help people with a hard-to-treat form of a genetic bleeding disorder known as Hemophilia A. The discovery and the results of pre-clinical tests appear in the May 2 issue of the Journal of Biological Chemistry.

19 May 2008